Abstract 5291
Background
The Irish Longitudinal Study on Ageing (TILDA) estimates that 13.1% of the Irish population is vitamin D3 deficient, compared with less than 6% of the US population surveyed in the National Health and Nutrition Examination Survey (NHANES). In recent years, numerous studies have shed light on a potential role for vitamin D3 in breast cancer risk modification and prognosis. We set out to assess the prevalence and clinical significance of vitamin D3 deficiency in women with breast cancer receiving chemotherapy in an Irish oncology dayward.
Methods
Retrospective chart review was conducted to collect data incuding patient age, cancer stage at diagnosis, date of treatment initiation and 25-hydroxy vitamin D3 (25(OH)D3) levels at start of treatment. Vitamin D3 deficiency was defined as a value <50 nmol/L. Charlson Comorbidity Index (CCI) was caluclated for all patients. Mean 25(OH)D3 levels by season (autumn, winter, spring, summer) were also caluclated. As the data set was not normally distributed, inter-group comparison was conducted using the Kruskal-Wallis Test with p < 0.05 considered significant.
Results
41 women had available baseline 25(OH)D3 levels and were included. 66% were deficient in 25(OH)D3 at baseline. The prevalence of vitamin D3 deficiency showed substantial seasonal variation, being highest in the winter months (88%) and lowest in the summer months (0%). Furthermore, mean 25(OH)D3 levels were lowest in the winter months (29.0nmol/L + 13.8) and highest in the summer months (66.3nmol/L + 11.5). The difference in mean 25(OH)D3 levels across the four seasons was significant (p = 0.022). Women who were deficient in vitamin D3 tended to be younger (p = 0.00001), have a higher cancer stage (p = 0.0071), and have a less favorable 10-year all cause mortality risk as indicated by their CCI (p = 0.0041).
Conclusions
We found a striking prevalence of 25(OH)D3 deficiency among women with breast cancer receiving adjuvant/neoadjuvant chemotherapy in an Irish oncology dayward. Notable seasonal variation in mean vitamin D3 levels was observed. Vitamin D3 deficiency was found to be more prevalent in younger women and was associated with a higher stage of breast cancer as well as a less favorable 10-year all cause mortality risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract
5629 - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Presenter: Luca Campedel
Session: Poster Display session 2
Resources:
Abstract